An Open Label, Adaptive, Phase 1 Trial of High‐Dose Oral Nitazoxanide in Healthy Volunteers: An Antiviral Candidate for SARS‐CoV‐2

Authors: Walker, Lauren E., FitzGerald, Richard, Saunders, Geoffrey, Lyon, Rebecca, Fisher, Michael, Martin, Karen, Eberhart, Izabela, Woods, Christie, Ewings, Sean, Hale, Colin, Rajoli, Rajith K. R., Else, Laura, Dilly‐Penchala, Sujan, Amara, Alieu, Lalloo, David G., Jacobs, Michael, Pertinez, Henry, Hatchard, Parys, Waugh, Robert, Lawrence, Megan, Johnson, Lucy, Fines, Keira, Reynolds, Helen, Rowland, Timothy, Crook, Rebecca, Okenyi, Emmanuel, Byrne, Kelly, Mozgunov, Pavel, Jaki, Thomas, Khoo, Saye, Owen, Andrew, Griffiths, Gareth, Fletcher, Thomas E.

Source: Clinical pharmacology & therapeutics. 111(3):585-594

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100140390782.0x000001&indx=1&recIds=ETOCvdc_100140390782.0x000001

Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a Phase I, open-label, dose-escalating, randomized controlled study

Authors: Khoo, Saye H, Fitzgerald, Richard, Fletcher, Thomas, Ewings, Sean, Jaki, Thomas, Lyon, Rebecca, Downs, Nichola, Walker, Lauren, Tansley-Hancock, Olana, Greenhalf, William, Woods, Christie, Reynolds, Helen, Marwood, Ellice, Mozgunov, Pavel, Adams, Emily, Bullock, Katie, Holman, Wayne, Bula, Marcin D, Gibney, Jennifer L, Saunders, Geoffrey, Corkhill, Andrea, Hale, Colin, Thorne, Kerensa, Chiong, Justin, Condie, Susannah, Pertinez, Henry, Painter, Wendy, Wrixon, Emma, Johnson, Lucy, Yeats, Sara, Mallard, Kim, Radford, Mike, Fines, Keira, Shaw, Victoria, Owen, Andrew, Lalloo, David G, Jacobs, Michael, Griffiths, Gareth

Source: Journal of antimicrobial chemotherapy. 76(12):3286-3295

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100135769669.0x000001&indx=1&recIds=ETOCvdc_100135769669.0x000001

RIVA – a phase IIa study of rituximab and varlilumab in relapsed or refractory B-cell malignancies: study protocol for a randomized controlled trial

Authors: Lim, Sean, Linton, Kim, Collins, Graham, Dhondt, Joke, Caddy, Joshua, Rossiter, Liz, Vadher, Karan, Fines, Keira, Rogers, Laura, Fernando, Diana, Stanton, Louise, Davies, Andrew, Johnson, Peter, Griffiths, Gareth

Source: Trials. 19(1):1-14

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100185401964.0x000001&indx=1&recIds=ETOCvdc_100185401964.0x000001

Clinical and Biological Effects of Combined CD27 and CD20 Antibody Therapy in Relapsed/Refractory B-Cell Lymphoma: The Riva Trial

Authors: Lim, Sean H, Sow, Heng Sheng, Wignall, Christopher, Mercer, Katy, Caddy, Josh, Boxall, Cherish, Thorne, Kerensa, Northey, Joshua, Stanton, Louise, Konn, Zoë, Fines, Keira, Medd, Patrick G., Coleman, Adam, Nunn, Lorna, Lown, Robert, McKay, Pamela, Osborne, Wendy, Linton, Kim, Collins, Graham P., Gentles, Andrew J, Rose-Zerilli, Matthew, Griffiths, Gareth

Source: In Blood 23 November 2021 138 Supplement 1:715-715

This result is not displayed to guests.
Login for full access.

This result is not displayed to guests.
Login for full access.